Efficacy of Dyslipidemia Control by Combination Therapy with Rosuvastatin 10 Mg and Ezetimibe 10 Mg Compared with Rosuvastatin 20 Mg Monotherapy in Patients with Chronic Coronary Syndromes: A Randomized, Single-blind Controlled Trial.
An Viet TranBao Lam Thai TranNghia Minh BuiAnh Tan To LeDiem Thi NguyenSon Kim TranToan Hoang NgoPublished in: Cardiovascular & hematological agents in medicinal chemistry (2024)
Group A's LDL-c reduction effect and target achievement proportion (Rosuvastatin 10mg + Ezetimibe 10 mg) were significantly higher than Group B's (Rosuvastatin 20 mg). Both medication therapies were safe in patients, and the increased dose of monotherapy showed more side effects than the combination therapy.
Keyphrases
- combination therapy
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- coronary artery
- open label
- coronary artery disease
- healthcare
- emergency department
- heart failure
- randomized controlled trial
- prognostic factors
- clinical trial
- peritoneal dialysis
- patient reported outcomes
- adverse drug
- transcatheter aortic valve replacement